Clinical trial
Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque…
NCT00141921 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00141921 |
|---|---|
| Title | Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis |
| Official title | An Open-Label Extension Study to Evaluate the Safety of Etanercept in Pediatric Subjects With Plaque Psoriasis |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pediatric Plaque Psoriasis |
| Intervention type | Drug |
| Interventions | Etanercept |
| Enrollment | 182 |
| Start date | Aug 11, 2005 |
| Primary completion | Dec 19, 2011 |
| Completion | Aug 16, 2017 |
| First posted | Sep 2, 2005 |
| Last update posted | Oct 5, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: